Condition

High Dose

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 2 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials2

Recruiting0

Common interventions3

Lead sponsors shown2

Clinical trials

2 shown

Efficacy of High-Dose Continuous Intravenous Magnesium Sulfate Infusion vs Standard Intravenous Magnesium Sulfate Therapy in Status Asthmaticus in the EDNCT07795970 · 2026-11-01

NOT_YET_RECRUITING

Methotrexate (Rheumatrex) High Dose Special Investigation (Regulatory Post Marketing Commitment Plan)NCT01414257 · 2011-05-01

COMPLETED

Common interventions

้High-dose Magnesium sulphateDRUG1 Methotrexate (MTX)DRUG1 standard-dose Magnesium SulfateDRUG1

Leading sponsors

Pfizer 1 Thammasat University 1

Trial status mix

COMPLETED1

NOT_YET_RECRUITING1

Phase mix

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.